An article in the current issue of the Archives of Internal Medicine explains how a computer based simulation model has found a link between short-term hormone therapy (HT) and improvements in life quality for women with menopausal symptoms. The article also points out that short-term hormone therapy may actually shorten life expectancy.
Hormone therapy (HT) provides women with the female hormones that decrease as they age. When the hormone estrogen is given alone, it is usually referred to as "ERT." When the hormone progestin is combined with estrogen, it is generally called "HT," formerly known as hormone replacement therapy (HRT).
The article outlines how decisions concerning menopausal hormone therapy (HT) are difficult due to the complexity of balancing the risks and benefits of this treatment. HT is an effective treatment for menopausal symptoms and decreases the risks of osteoporosis and colorectal cancer, but it may also increase the risk of coronary heart disease, stroke, blood clots and breast cancer.
Nananda F. Col, M.D., M.P.P., M.P.H., of Rhode Island Hospital, Providence, and colleagues investigated which women would benefit from short-term HT by weighing symptom relief against risks of causing disease.
The researchers developed a Web-based computer model to simulate the effects of short-term HT use (two years) on life expectancy and quality-adjusted life expectancy (QALE, a measurement of the number of high quality of life years that can be expected over the course of a lifetime) among 50-year-old menopausal women (without hysterectomy). The researchers based their model on findings from the Women's Health Initiative, which reported on some of the risks associated with HT.